Results 1 to 10 of about 182,500 (270)

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

open access: yesBMC Cancer
Background Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly selective inhibitor of IDO1.
Irfan Cicin   +15 more
doaj   +1 more source

Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients

open access: yesPharmacological Research
Background: Pembrolizumab is a standard first-line treatment for metastatic non–small cell lung cancer (NSCLC). Although approved dosing regimens achieve near-maximal PD-1 receptor occupancy in clinical trials, variability in pembrolizumab exposure in ...
Cristina Martínez-Toledo   +27 more
doaj   +1 more source

Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies

open access: yesJournal of Cancer Research and Clinical Oncology
Background Although pembrolizumab has been shown to be effective, its high price has prevented it from being widely used. Especially in the real world, the application situation is still uncertain.
Ning Wan   +15 more
doaj   +1 more source

A case of severe visual loss related to treatment with pembrolizumab for metastatic renal pelvic cancer

open access: yesIJU Case Reports
Introduction Pembrolizumab is the standard therapy for urothelial carcinoma treatment; however, adverse events have been noted. Here, we report a rare case of vision loss as an immune‐related adverse event of pembrolizumab therapy in a patient with ...
Naoki Inoue   +5 more
doaj   +1 more source

Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer

open access: yesCost Effectiveness and Resource Allocation
Background Programmed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (NPC).
Jing Nie   +6 more
doaj   +1 more source
Some of the next articles are maybe not open access.

Home - About - Disclaimer - Privacy